Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, International Journal of Cancer, vol.13, issue.5, pp.359-86, 2015. ,
DOI : 10.1016/S1470-2045(12)70137-7
The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?, Liver International, vol.34, issue.10, 2016. ,
DOI : 10.1053/jhep.2001.27219
Cirrhotomimetic Type Hepatocellular Carcinoma Diagnosed After Liver Transplantation???Eighteen Months of Follow-up: A Case Report, Transplantation Proceedings, vol.40, issue.8, 2008. ,
DOI : 10.1016/j.transproceed.2008.07.012
Diffuse Cirrhosis-like Hepatocellular Carcinoma, The American Journal of Surgical Pathology, vol.34, issue.7, pp.935-976, 2010. ,
DOI : 10.1097/PAS.0b013e3181ddf52f
Hepatocellular Carcinoma: Illustrated Guide to Systematic Radiologic Diagnosis and Staging According to Guidelines of the American Association for the Study of Liver Diseases, RadioGraphics, vol.33, issue.6, pp.1653-68, 2013. ,
DOI : 10.1148/rg.336125104
A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver, pp.280-289, 1981. ,
Epidemiology of HCC: Consider the Population, J Clin Gastroenterol. 2013, vol.47, issue.0, pp.2-6 ,
Hepatocellular carcinoma: Diagnosis and treatment, Gastroenterology, vol.122, issue.6, pp.1609-1628, 2002. ,
DOI : 10.1053/gast.2002.33411
Screening for cancer in viral hepatitis. Clin Liver Dis, Feb, vol.5, issue.1, pp.109-131, 2001. ,
Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: univariate and multivariate analysis, The American Journal of Gastroenterology, vol.35, issue.3, pp.1243-50, 2001. ,
DOI : 10.1016/S0002-9270(99)00913-2
Role of serum alpha-fetoprotein in preand post-orthotopic liver transplantation (OLT) for malignant disease, J Nucl Med Allied Sci, vol.33, issue.3, pp.132-136, 1989. ,
Serum Alpha-Fetoprotein Estimations and Doubling Time in Hepatocellular Carcinoma: Influence of Therapy and Possible Value in Early Detection, JNCI: Journal of the National Cancer Institute, vol.64, issue.6, pp.1329-1361, 1980. ,
DOI : 10.1093/jnci/64.6.1329
An assessment of therapeutic effect of hepatocellular carcinoma by the serial changes in serum AFP value]. Nihon Shokakibyo Gakkai Zasshi, pp.100-108, 1990. ,
Favorable ??-fetoprotein decrease as a prognostic surrogate in patients with hepatocellular carcinoma after radiofrequency ablation, Journal of Gastroenterology and Hepatology, vol.44, issue.2, pp.605-617, 2010. ,
DOI : 10.1002/hep.21408
Diffuse Infiltrative Hepatocellular Carcinoma: Assessment of Presentation, Treatment, and Outcomes, Annals of Surgical Oncology, vol.53, issue.9, pp.2897-907, 2012. ,
DOI : 10.1002/hep.23725
Infiltrative Hepatocellular Carcinoma: Natural History and Comparison with Multifocal, Nodular Hepatocellular Carcinoma, Annals of Surgical Oncology, vol.190, issue.Suppl 4, pp.1075-82, 2015. ,
DOI : 10.1007/978-3-642-16037-0_6
EASL?EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma, Journal of Hepatology, vol.56, issue.4, pp.908-951, 2012. ,
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid???enhanced MR Imaging, Radiology, vol.261, issue.3, pp.834-878, 2011. ,
DOI : 10.1148/radiol.11101840
Hepatocellular Carcinoma: Imaging Patterns on Gadoxetic Acid???enhanced MR Images and Their Value as an Imaging Biomarker, Radiology, vol.267, issue.3, pp.776-86, 2013. ,
DOI : 10.1148/radiol.13120775
CT and MRI Improve Detection of Hepatocellular Carcinoma, Compared With Ultrasound Alone, in Patients With Cirrhosis, Clinical Gastroenterology and Hepatology, vol.9, issue.2, pp.161-168, 2011. ,
DOI : 10.1016/j.cgh.2010.09.017
Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus?, American Journal of Roentgenology, vol.165, issue.3, pp.573-580, 1995. ,
DOI : 10.2214/ajr.165.3.7645473
Differentiating malignant from benign thrombosis in hepatocellular carcinoma: contrast-enhanced ultrasound, Abdominal Imaging, vol.160, issue.6, pp.153-61, 2014. ,
DOI : 10.2214/ajr.160.6.8388621
Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations, Journal of Magnetic Resonance Imaging, vol.217, issue.2, pp.189-95, 2003. ,
DOI : 10.1002/jmri.10336
Infiltrative Hepatocellular Carcinoma: What Radiologists Need to Know, RadioGraphics, vol.35, issue.2, pp.371-86 ,
DOI : 10.1148/rg.352140114
Using Gd-EOB-DTPA-enhanced 3-T MRI for the differentiation of infiltrative hepatocellular carcinoma and focal confluent fibrosis in liver cirrhosis, Magnetic Resonance Imaging, vol.31, issue.7, pp.1137-1179, 2013. ,
DOI : 10.1016/j.mri.2013.01.011
Management of hepatocellular carcinoma, Hepatology, vol.35, issue.5, pp.1020-1022, 2011. ,
DOI : 10.1016/0016-5085(88)90436-2
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan, Liver Cancer, vol.3, issue.3-4, pp.3-4458, 2014. ,
DOI : 10.1159/000343875
Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer, pp.85-95, 2015. ,
LI-RADS (Liver Imaging Reporting and Data System): Summary, discussion, and consensus of the LI-RADS Management Working Group and future directions, Hepatology, vol.20, issue.Suppl. 1, pp.1056-65, 2015. ,
DOI : 10.1016/j.acra.2013.01.016
Fine needle biopsy of focal liver lesions: The hepatologist's point of view, Liver Transplantation, vol.199, issue.S2, pp.26-35, 2004. ,
DOI : 10.1148/radiology.199.3.8637995
Liver Biopsy, New England Journal of Medicine, vol.344, issue.7, pp.495-500, 2001. ,
DOI : 10.1056/NEJM200102153440706
Ultrasound-guided cutting biopsy for the diagnosis of hepatocellular carcinoma ??? a study based on 420 patients, Journal of Hepatology, vol.25, issue.3, pp.334-342, 1996. ,
DOI : 10.1016/S0168-8278(96)80120-6
Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma, Journal of Hepatology, vol.35, issue.2, pp.254-262, 2001. ,
DOI : 10.1016/S0168-8278(01)00108-8
Percutaneous fine-needle aspiration cytology in the diagnosis and management of liver tumours, British Journal of Surgery, vol.43, issue.6, 2002. ,
DOI : 10.1046/j.1365-2168.2002.02111.x
Extrahepatic Metastases of Hepatocellular Carcinoma, Radiology, vol.216, issue.3, pp.698-703, 2000. ,
DOI : 10.1148/radiology.216.3.r00se24698
Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment, J Nucl Med, vol.33, issue.3, pp.333-342, 1992. ,
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma, Gastroenterology, vol.150, issue.4, pp.835-53, 2016. ,
DOI : 10.1053/j.gastro.2015.12.041
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification, Seminars in Liver Disease, vol.19, issue.03, pp.329-367, 1999. ,
DOI : 10.1055/s-2007-1007122
Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort, Hepatology, vol.49, issue.4, pp.707-723, 2005. ,
DOI : 10.1080/13651820310015833
Sorafenib in Advanced Hepatocellular Carcinoma, New England Journal of Medicine, vol.359, issue.4, pp.378-90, 2008. ,
DOI : 10.1056/NEJMoa0708857
Role of Raf Kinase in Cancer: Therapeutic Potential of Targeting the Raf/MEK/ERK Signal Transduction Pathway, Seminars in Oncology, vol.33, issue.4, 2006. ,
DOI : 10.1053/j.seminoncol.2006.04.002
Sorafenib Blocks the RAF/MEK/ERK Pathway, Inhibits Tumor Angiogenesis, and Induces Tumor Cell Apoptosis in Hepatocellular Carcinoma Model PLC/PRF/5, Cancer Research, vol.66, issue.24, pp.11851-11859, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-1377
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nature Reviews Drug Discovery, vol.47, issue.10, pp.835-879, 2006. ,
DOI : 10.4161/cc.3.2.648
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models, Cancer Chemotherapy and Pharmacology, vol.64, issue.Suppl 2, pp.561-74, 2007. ,
DOI : 10.1007/s00280-006-0393-4
Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations, Therapeutic Advances in Gastroenterology, vol.23, issue.6, 2013. ,
DOI : 10.1093/annonc/mdr584
URL : http://journals.sagepub.com/doi/pdf/10.1177/1756283X13498540
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial, The Lancet Oncology, vol.10, issue.1, pp.25-34, 2009. ,
DOI : 10.1016/S1470-2045(08)70285-7
Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.33, issue.2, pp.172-181, 2015. ,
DOI : 10.1200/JCO.2013.54.3298
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.31, issue.32, pp.314067-75, 2013. ,
DOI : 10.1200/JCO.2012.45.8372
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study, Journal of Clinical Oncology, vol.31, issue.28, pp.313517-313541, 2013. ,
DOI : 10.1200/JCO.2012.48.4410
SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma, Journal of Clinical Oncology, vol.33, issue.6, 2014. ,
DOI : 10.1200/JCO.2013.53.7746
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. The Oncologist, pp.379-80, 2013. ,
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study, Oncotarget, vol.7, issue.39, 2016. ,
DOI : 10.18632/oncotarget.10794
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma, Annals of Oncology, vol.26, issue.12, pp.2457-63, 2015. ,
DOI : 10.1093/annonc/mdv388
Reporting results of cancer treatment. Cancer, pp.207-221, 1981. ,
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, 2009. ,
DOI : 10.1016/j.ejca.2008.10.026
Crit??res de la r??ponse tumorale en imagerie??: RECIST, mRECIST, Cheson, Journal de Radiologie Diagnostique et Interventionnelle, vol.95, issue.7-8, 2014. ,
DOI : 10.1016/j.jradio.2014.03.024
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference, Journal of Hepatology, vol.35, issue.3, pp.421-451, 2001. ,
DOI : 10.1016/S0168-8278(01)00130-1
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis, Feb, vol.30, issue.1, pp.52-60, 2010. ,
DOI : 10.1055/s-0030-1247132
URL : http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0030-1247132.pdf
Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version), Hepatology Research, vol.30, issue.1, pp.3-9, 2016. ,
DOI : 10.1055/s-0030-1247132
Quantitative and Volumetric EASL and RECIST: Feasibility of a Semi-automated Software Method to Assess Tumor Response after Transcatheter Arterial Chemoembolization (TACE), J Vasc Interv Radiol, 2012. ,
Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach, Radiology, vol.278, issue.1, pp.275-84, 2015. ,
DOI : 10.1148/radiol.2015142951
Assessment of Tumor Necrosis of Hepatocellular Carcinoma After Chemoembolization: Diffusion-Weighted and Contrast-Enhanced MRI With Histopathologic Correlation of the Explanted Liver, American Journal of Roentgenology, vol.193, issue.4, pp.1044-52, 2009. ,
DOI : 10.2214/AJR.08.1461
Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging., Radiology, vol.204, issue.3, pp.739-783, 1997. ,
DOI : 10.1148/radiology.204.3.9280252
Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part I. Identification and Validation of Volumetric Functional Response Criteria, Radiology, vol.268, issue.2, 2013. ,
DOI : 10.1148/radiol.13122307
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721055/pdf
Hepatocellular Carcinoma: Response to TACE Assessed with Semiautomated Volumetric and Functional Analysis of Diffusion-weighted and Contrast-enhanced MR Imaging Data, Radiology, vol.260, issue.3, 2011. ,
DOI : 10.1148/radiol.11102330
Unresectable Hepatocellular Carcinoma: MR Imaging after Intraarterial Therapy. Part II. Response Stratification Using Volumetric Functional Criteria after Intraarterial Therapy, Radiology, vol.268, issue.2, 2013. ,
DOI : 10.1148/radiol.13121637
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3721055/pdf
Diffusion-Weighted MR Imaging of Hepatocellular Carcinoma: Current Value in Clinical Evaluation of Tumor Response to Locoregional Treatment, Journal of vascular and interventional radiology, 2016. ,
DOI : 10.1016/j.jvir.2015.10.003
Unresectable Hepatocellular Carcinoma: Serial Early Vascular and Cellular Changes after Transarterial Chemoembolization as Detected with MR Imaging, Radiology, vol.250, issue.2, pp.466-73, 2009. ,
DOI : 10.1148/radiol.2502072222
Early Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization: Choline Levels and MR Diffusion Constants???Initial Experience, Radiology, vol.239, issue.2, pp.448-56, 2006. ,
DOI : 10.1148/radiol.2392042202
Diffusionweighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization. World journal of gastroenterology, pp.3161-3168, 2010. ,
Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR American journal of roentgenology, pp.795-800, 2013. ,
DOI : 10.2214/ajr.12.9798
URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4144815/pdf
Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World journal of gastroenterology, pp.5993-6000, 2010. ,
Transcatheter Intraarterial Perfusion: MR Monitoring of Chemoembolization for Hepatocellular Carcinoma???Feasibility of Initial Clinical Translation, Radiology, vol.246, issue.3, pp.964-71, 2008. ,
DOI : 10.1148/radiol.2463070725
Four-dimensional Transcatheter Intraarterial Perfusion MR Imaging for Monitoring Chemoembolization of Hepatocellular Carcinoma: Preliminary Results, Journal of Vascular and Interventional Radiology, vol.19, issue.11, pp.1589-95, 2008. ,
DOI : 10.1016/j.jvir.2008.08.010
Quantitative 4D transcatheter intraarterial perfusion MRI for monitoring chemoembolization of hepatocellular carcinoma, Journal of Magnetic Resonance Imaging, vol.34, issue.182, pp.1106-1122, 2010. ,
DOI : 10.2214/ajr.176.3.1760667
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil, Journal of Hepatology, vol.55, issue.4, pp.858-65, 2011. ,
DOI : 10.1016/j.jhep.2011.01.032
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study, Journal of Clinical Oncology, vol.27, issue.18, pp.3027-3062, 2009. ,
DOI : 10.1200/JCO.2008.20.9908
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy, Journal of Hematology & Oncology, vol.6, issue.1, 2013. ,
DOI : 10.1200/JCO.2005.02.2574
Pretreatment DCE-MRI for prediction of PFS in patients with inoperable HCC treated with TACE. Cancer Imaging, pp.114-114, 2011. ,
Correlation of Computed Tomography and Positron Emission Tomography in Patients With Metastatic Gastrointestinal Stromal Tumor Treated at a Single Institution With Imatinib Mesylate: Proposal of New Computed Tomography Response Criteria, Journal of Clinical Oncology, vol.25, issue.13, pp.1753-1762, 2007. ,
DOI : 10.1200/JCO.2006.07.3049
We Should Desist Using RECIST, at Least in GIST, Journal of Clinical Oncology, vol.25, issue.13, pp.1760-1764, 2007. ,
DOI : 10.1200/JCO.2006.07.3411
Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma, Oncol Lett, vol.6, issue.6, pp.1707-1719, 2013. ,
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma, Cancer, vol.24, issue.suppl 2, pp.147-56, 2012. ,
DOI : 10.1200/JCO.2005.03.6723
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib, The Oncologist, vol.19, issue.4, pp.2014394-402 ,
DOI : 10.1634/theoncologist.2013-0114
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma, Journal of Gastroenterology, vol.97, issue.12, pp.1578-87, 2014. ,
DOI : 10.1002/cncr.11111
Identification of Responders to Sorafenib in Hepatocellular Carcinoma: Is Tumor Volume Measurement the Way Forward?, Oncology, vol.86, issue.4, pp.191-199, 2014. ,
DOI : 10.1159/000358599
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib, Clinical and Molecular Hepatology, vol.20, issue.2, pp.218-240 ,
DOI : 10.3350/cmh.2014.20.2.218
A Quantitative Analysis Correlated with FDG PET Findings, American Journal of Roentgenology, vol.183, issue.6, 2004. ,
DOI : 10.2214/ajr.183.6.01831619
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1, European Journal of Radiology, vol.85, issue.1, 2016. ,
DOI : 10.1016/j.ejrad.2015.10.024
Assessing tumor response after loco-regional liver cancer therapies: the role of 3D MRI, Expert Review of Anticancer Therapy, vol.21, issue.3, 2015. ,
DOI : 10.1016/j.acra.2013.11.006
A Quantitative Analysis Correlated with FDG PET Findings, American Journal of Roentgenology, vol.183, issue.6, pp.1619-1647, 2004. ,
DOI : 10.2214/ajr.183.6.01831619